HomeAI · summaries
Storia in 3 fonti
FDA Approves Pfizer’s IBRANCE Regimen for HR+, HER2+ Metastatic Breast Cancer Frontline Maintenance
FDA Approves Pfizer’s IBRANCE Regimen for HR+, HER2+ Metastatic Breast Cancer Frontline Maintenance
Confronto fonti
3 prospettive sulla stessa storiaTimeline cronologica
- ·
healio.com
Ibrance nabs FDA approval for HR-positive, HER2-positive metastatic breast cancer
The FDA has approved the first and only cyclin-dependent kinase 4/6 inhibitor for patients with HR-positive metastatic breast cancer, regardless of HER2 status. Palbociclib…
- ·
medpagetoday.com
FDA Approves CDK4/6 Inhibitor for HER2-Positive Breast Cancer
PATINA trial paved the way for palbociclib-based frontline maintenance regimen
- ·
morningstar.com
FDA Approves Pfizer’s IBRANCE Regimen for HR+, HER2+ Metastatic Breast Cancer Frontline Maintenance
FDA Approves Pfizer’s IBRANCE Regimen for HR+, HER2+ Metastatic Breast Cancer Frontline Maintenance